{"id":62807,"date":"2026-04-10T23:17:44","date_gmt":"2026-04-10T15:17:44","guid":{"rendered":"https:\/\/flcube.com\/?p=62807"},"modified":"2026-04-10T23:17:45","modified_gmt":"2026-04-10T15:17:45","slug":"beone-medicines-secures-nmpa-conditional-approval-for-imdelltra-tarlatamab-in-heavily-pretreated-small-cell-lung-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62807","title":{"rendered":"BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer"},"content":{"rendered":"\n

BeOne Medicines Ltd.<\/strong> (NASDAQ: ONC<\/a>, HKG: 6160<\/a>, SHA: 688235<\/a>), formerly BeiGene, announced that China\u2019s National Medical Products Administration (NMPA)<\/strong> has granted conditional marketing approval<\/strong> for Imdelltra\u2122 (tarlatamab)<\/strong>, a DLL3-targeting bispecific T-cell engager (BiTE\u00ae)<\/strong> therapy developed in partnership with Amgen Inc.<\/strong> (NASDAQ: AMGN). The indication covers adult patients with extensive-stage small cell lung cancer (ES-SCLC)<\/strong> who have progressed after at least two prior systemic therapies<\/strong>, including platinum-based chemotherapy.<\/p>\n\n\n\n

Regulatory Milestone Summary<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Drug Name<\/strong><\/td>Imdelltra (tarlatamab)<\/td><\/tr>
Class<\/strong><\/td>Bispecific T-cell Engager (BiTE\u00ae)<\/td><\/tr>
Target<\/strong><\/td>DLL3 (tumor) \u00d7 CD3 (T cell)<\/td><\/tr>
Indication<\/strong><\/td>Third-line+ ES-SCLC<\/td><\/tr>
Approval Authority<\/strong><\/td>NMPA (China)<\/td><\/tr>
Approval Type<\/strong><\/td>Conditional (subject to confirmatory data)<\/td><\/tr>
Commercial Lead<\/strong><\/td>BeOne Medicines (mainland China)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

This approval enables immediate patient access under China\u2019s accelerated pathway for breakthrough oncology therapies addressing critical unmet needs.<\/p>\n\n\n\n

Clinical & Market Context<\/h2>\n\n\n\n
    \n
  • Disease Burden:<\/strong> ES-SCLC is an aggressive neuroendocrine malignancy with limited treatment options beyond second-line; median survival in refractory settings is typically <6 months<\/li>\n\n\n\n
  • DLL3 Rationale:<\/strong> Expressed in >85% of SCLC tumors but absent in most healthy tissues, making it an ideal target for T-cell redirection<\/li>\n\n\n\n
  • Global Foundation:<\/strong> Approval supported by Amgen\u2019s international Phase II DeLLphi-301 trial, which showed objective response rates exceeding 40% and durable disease control in heavily pretreated patients<\/li>\n\n\n\n
  • Safety Profile:<\/strong> Manageable cytokine release syndrome (mostly Grade 1\u20132) with established mitigation protocols<\/li>\n<\/ul>\n\n\n\n

    Strategic Partnership Dynamics<\/h2>\n\n\n\n

    The approval validates the 2019 global collaboration<\/strong> between BeOne and Amgen, under which BeOne holds exclusive rights to develop, file, and commercialize<\/strong> Imdelltra in mainland China. BeOne will deploy its nationwide oncology infrastructure\u2014spanning over 1,800 hospitals<\/strong>\u2014to drive rapid market access and physician adoption.<\/p>\n\n\n\n

      \n
    • Reimbursement Strategy:<\/strong> Expected submission to National Reimbursement Drug List (NRDL) negotiations in 2026<\/li>\n\n\n\n
    • Competitive Edge:<\/strong> First-in-class DLL3-targeted therapy in China; no approved BiTEs for solid tumors previously<\/li>\n\n\n\n
    • Pipeline Leverage:<\/strong> Success strengthens joint development framework for additional Amgen assets in BeOne\u2019s portfolio<\/li>\n<\/ul>\n\n\n\n

      Forward-Looking Statements<\/strong>
      This brief contains forward-looking statements regarding regulatory status, commercial rollout, and clinical outcomes. Actual results may differ due to post-marketing requirements, competitive dynamics, and real-world adoption patterns.<\/p>\n","protected":false},"excerpt":{"rendered":"

      BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that China\u2019s National…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[330,2092,16,847,3046,15,848],"class_list":["post-62807","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-amgen","tag-beone-medicines","tag-cancer","tag-hkg-6160","tag-nasdaq-onc","tag-product-approvals","tag-sha-688235"],"yoast_head":"\nBeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that China\u2019s National Medical Products Administration (NMPA) has granted conditional marketing approval for Imdelltra\u2122 (tarlatamab), a DLL3-targeting bispecific T-cell engager (BiTE\u00ae) therapy developed in partnership with Amgen Inc. (NASDAQ: AMGN). The indication covers adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have progressed after at least two prior systemic therapies, including platinum-based chemotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62807\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer\" \/>\n<meta property=\"og:description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that China\u2019s National Medical Products Administration (NMPA) has granted conditional marketing approval for Imdelltra\u2122 (tarlatamab), a DLL3-targeting bispecific T-cell engager (BiTE\u00ae) therapy developed in partnership with Amgen Inc. (NASDAQ: AMGN). The indication covers adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have progressed after at least two prior systemic therapies, including platinum-based chemotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62807\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-10T15:17:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-10T15:17:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62807#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62807\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer\",\"datePublished\":\"2026-04-10T15:17:44+00:00\",\"dateModified\":\"2026-04-10T15:17:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62807\"},\"wordCount\":345,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Amgen\",\"BeOne Medicines\",\"Cancer\",\"HKG: 6160\",\"NASDAQ: ONC\",\"Product approvals\",\"SHA: 688235\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62807#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62807\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62807\",\"name\":\"BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-10T15:17:44+00:00\",\"dateModified\":\"2026-04-10T15:17:45+00:00\",\"description\":\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that China\u2019s National Medical Products Administration (NMPA) has granted conditional marketing approval for Imdelltra\u2122 (tarlatamab), a DLL3-targeting bispecific T-cell engager (BiTE\u00ae) therapy developed in partnership with Amgen Inc. (NASDAQ: AMGN). The indication covers adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have progressed after at least two prior systemic therapies, including platinum-based chemotherapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62807#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62807\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62807#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer - Insight, China's Pharmaceutical Industry","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that China\u2019s National Medical Products Administration (NMPA) has granted conditional marketing approval for Imdelltra\u2122 (tarlatamab), a DLL3-targeting bispecific T-cell engager (BiTE\u00ae) therapy developed in partnership with Amgen Inc. (NASDAQ: AMGN). The indication covers adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have progressed after at least two prior systemic therapies, including platinum-based chemotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62807","og_locale":"en_US","og_type":"article","og_title":"BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer","og_description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that China\u2019s National Medical Products Administration (NMPA) has granted conditional marketing approval for Imdelltra\u2122 (tarlatamab), a DLL3-targeting bispecific T-cell engager (BiTE\u00ae) therapy developed in partnership with Amgen Inc. (NASDAQ: AMGN). The indication covers adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have progressed after at least two prior systemic therapies, including platinum-based chemotherapy.","og_url":"https:\/\/flcube.com\/?p=62807","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-10T15:17:44+00:00","article_modified_time":"2026-04-10T15:17:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62807#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62807"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer","datePublished":"2026-04-10T15:17:44+00:00","dateModified":"2026-04-10T15:17:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62807"},"wordCount":345,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Amgen","BeOne Medicines","Cancer","HKG: 6160","NASDAQ: ONC","Product approvals","SHA: 688235"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62807#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62807","url":"https:\/\/flcube.com\/?p=62807","name":"BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-10T15:17:44+00:00","dateModified":"2026-04-10T15:17:45+00:00","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that China\u2019s National Medical Products Administration (NMPA) has granted conditional marketing approval for Imdelltra\u2122 (tarlatamab), a DLL3-targeting bispecific T-cell engager (BiTE\u00ae) therapy developed in partnership with Amgen Inc. (NASDAQ: AMGN). The indication covers adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have progressed after at least two prior systemic therapies, including platinum-based chemotherapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62807#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62807"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62807#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62807"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62807\/revisions"}],"predecessor-version":[{"id":62809,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62807\/revisions\/62809"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}